U.S. Markets closed

Hikma Pharmaceuticals PLC (HIK.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,423.00+17.00 (+1.21%)
At close: 4:35PM BST
People also watch
SHP.LAHT.LBAB.LHL.LITRK.L

Hikma Pharmaceuticals PLC

1 New Burlington Place
London W1S 2HR
United Kingdom
44 20 7399 2760
http://www.hikma.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees8,500

Key Executives

NameTitlePayExercisedAge
Mr. Said Samih Taleb DarwazahChairman & CEON/AN/A60
Mr. Mazen Samih Taleb DarwazehExec. Vice Chairman, CEO and Pres of MENA & Emerging MarketsN/AN/A59
Mr. Khalid NabilsiChief Financial OfficerN/AN/A42
Ms. Susan RingdalVP of Corp. Strategy & Investor RelationsN/AN/AN/A
Mr. Hussein ArkhaghaGen. CounselN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segment’s principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segment’s principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segment’s principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.

Corporate Governance

Hikma Pharmaceuticals PLC’s ISS Governance QualityScore as of July 1, 2017 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.